INTRODUCTION
Condoms are a highly effective means of preventing human immunode® ciency virus (HIV) transmission and their use is increasing in many parts of the world. Currently, the only widely-available effective method to prevent the heterosexual transmission of HIV is the use of male condoms. However, even where HIV prevalence is high, as is the case in some developing countries, condom promotion projects, involving constant condom availability and regular counselling, have been unable to attain levels of use above 70% except in limited targeted populations 1, 2 .
The world's ® rst female condom (Reality, Femidom, and Femy are all registered names for the female condom) became available to the public in 1992. For ® ve years prior to its introduction in 1992 and continuing since then, clinical studies have been conducted to evaluate ef® cacy, acceptability and safety.
The studies have satis® ed ef® cacy, safety, and acceptability standards established by government regulatory bodies including the United States Food and Drug Administration (FDA), and the product has received the European CE mark.
Additional studies addressing operational issues, such as introduction strategies, education, marketing and distribution programmes, are increasing trial, acceptance and availability of the female condom, particularly to at-risk populations.
The female condom extends the choice of contraceptive methods available and provides signi® cant protection from the risk of pregnancy and infection with sexually transmitted diseases (STDs). Most women and men participating in the clinical studies report that the female condom is acceptable and allows them to practise safer sex that is sensitive and pleasurable.
Data from studies around the world have highlighted the need for female-controlled prevention methods. Non-consensual sex, fear of violence, economic dependence, and inability to negotiate male condom use restrict prevention options for many women 3 . Although the female condom requires male cooperation, it does not require male initiative. Most importantly, use of the female condom reduces the number of unprotected acts of sexual intercourse, thereby decreasing the risk of pregnancy and increasing protection against transmission of STDs, including HIV.
AIDS is now a leading cause of death among women in developing countries 4 . Women at all ages are biologically at higher risk than men for contracting HIV 5 . The majority of these infections are transmitted through vaginal intercourse; the presence of other STD infections can substantially increase women's chances of becoming infected with HIV 6 .
The design of the female condom offers an extra measure of safety to women that the male condom does not. Because the outer ring of the female condom partially covers the external genitalia 7 , the female condom may be particularly bene® cial in preventing infections caused by genital ulcer pathogens, such as herpes and chancroid. Furthermore, the female condom covers the vaginal mucosa, and thus may provide better protection from STDs than diaphragms, sponges, and caps that cover the cervical mucosa only 8 .
In vitro studies have shown that the female condom provides an effective barrier to passage of microorganisms including HIV 9, 10 . The female condom blocked passage of a bacteriophage smaller than hepatitis B, the smallest virus known to cause an STD, and one-quarter the size of HIV. One study of STD reinfection rates in 104 sexually active women with documented trichomonas and/or chlamydia infection demonstrated that none of the 54 participants who consistently used the female condom were reinfected. Non-compliant users and the control group had trichomonas reinfection rates of 14.7% and 14%, respectively. Three non-compliant users were reinfected with chlamydia 11 .
In a study of Thai sex workers 12 randomly allocated to receive either male or female condoms, there was a 25% reduction in the geometric mean incidence rate of STDs in the sex establishments using the female condom compared with those using the male condom (2.81/1000 vs. 3.69/100 women-weeks).
Using an acceptable statistical model and extrapolating from failure rates for correct and consistent use, calculations estimate a 97.1% reduction in the risk of HIV infection for each act of intercourse with correct use of the female condom 13 .
EFFICACY OF FEMALE CONDOM

Ef® cacy in prevention of STIs/HIV infection
Clinical studies in vitro con® rm that the female condom can provide an effective barrier to organisms smaller than those known to cause sexually transmitted diseases. Independent studies, as well as those performed by Chartex, demonstrate that the female condom provides an effective barrier to gases, liquids and microorganisms including cytomegalovirus, herpes virus, hepatitis B virus, and HIV 9, 10 . A recent study by UNAIDS in Thailand shows that use of the female condom can lead to a reduction in STDs. Some groups of commercial sex workers were given male condoms only, others were given both male condoms and female condoms. Among those supplied with female condoms the number of unprotected sex acts was fewer and the incidence of sexually transmitted infections (STIs) was one-third lower 12 .
Ef® cacy in preventing pregnancy
Contraceptive ef® cacy of the female condom has had very limited assessment. The six-month gross cumulative accidental pregnancy rate was 12.4% in the US population and 22.2% in Latin American, resulting in an overall failure rate of 15.1%. The estimated failure rate was 21.1% per 100 womenyears of use. Among those women who used the female condom correctly for every act of intercourse, pregnancy rates were 2.6% among the participants from the US and 9.5% among those from Latin America. This results in an overall pregnancy rate of 4.3% per 100 women-years. In addition, of the 221 US women, 33.5% discontinued, whereas 55.1% of the 107 Latin American women discontinued. Overall the very limited evidence available indicates that the female condom, when used consistently and correctly, can be a highly effective method of contraception 14 .
ACCEPTABILITY
Among sex workers and their clients in Thailand, the female condom was tested in Khon Kaen, to determine if it might be an acceptable method of protection from STDs for high-risk women 15± 18 . During the two weeks of the study, the 20 volunteers had 247 acts of vaginal intercourse. Twenty at-risk women in Khon Kaen were trained to use the female condom and supplied with 20 unlubricated devices each. They were also provided with a supply of spermicidal lubricant and their regular supply of male condoms. The participants were instructed about the risk of AIDS and advised that they could use the female condom as an alternative method of protection to the male condom. The decision of which device to use, if any, was left to the participant.
Participants were interviewed two weeks later, the 20 volunteers had 247 acts of vaginal intercourse.
They reported using the female condom alone in a total of 78 of 247 episodes (32%), the male condom was used in 90 of the episodes (35%) and none in 87 episodes (33%). Two-thirds of the volunteers reported no aversion to the female condom while one-third disliked it. Mechanically, the female condom performed well, no rips or tears were reported during intercourse. Eighteen of 20 participants said they would advise other sex workers to try these female condoms; 13 of them said that they would like to use the female condom in the future. Nineteen out of 20 participants said the female condom was less convenient to use than the male condom, and six said it was less comfortable, and it bothered them to insert the condom by themselves. Most of them reported that it was too long (17 cms) and too wide (7 cms) also, the need to lubricate the condoms made their use messy and inconvenient. These problems can be overcome by shortening and pre-lubricating the condoms. Most discontinued using the device because of male partner objection 16 . Based on these results, we decided to repeat this study in Khon Kaen with a shorter (15 mm), pre-lubricated version of the female condom.
The second trial 17 therefore was`Consumer Preference Study of a Modi® ed Female Condom in a Sexually Active Population at Risk of Contracting AIDS'. Twenty prostitutes aged 19 to 26 years evaluated the modi® ed female condom during 132 acts of coitus (18% of episodes). Seventyone per cent of the participants liked the condom while four of them (19%) reported that all of their clients disliked the condom; 95% of the users reported that the condom stayed in place during intercourse. It is not dif® cult to remove and almost all respondents felt competent in using it and 90% would recommend it to others. Nevertheless, less than half of the users would like to use the female condom in the future. The reasons for discontinuing use of the female condom were that it was inconvenient and painful. The modi® ed female condom does cause pain in the majority of users.
This trial of a modi® ed female condom has found that structural problems remain with regard to the inner ring, size and the spread of the lubricant to the outside of the condom which makes it dif® cult to handle and insert. However, it is not possible to assess whether pre-lubricating the condom improved sensation. Nevertheless, the shortening of the length of the condom may have had an impact in improved positioning of the device. At the same time, the modi® ed condom generally received more favourable reactions by this group of prostitutes than the previous condom did in the ® rst trial. More women continued using the condom in the second trial and nearly twice the number of condoms was tested in the ® rst trial than in the second trial. When there is a choice, however, the women (and presumably the men) will choose the male condom. Thus, for this group of Thai prostitutes, it would seem that the female condom is only meaningful as an alternative to sex without any protection from STD and HIV.
Although continued modi® cations to the structure and improvement in lubrication of the female condom would probably reduce complaints, it is not likely that these modi® cations would signi®cantly improve acceptability of the female condom among prostitutes. Instead, the improved acceptability of the female condom in the near future will probably be determined by the increasing spread and fear of HIV infection.
These two acceptability trials have demonstrated that even prostitutes with minimal education can be easily trained to insert and remove the female condom. Continued demand for the female condoms after the research supply was exhausted is also an indication that prostitutes would continue to use the female condom but on a limited basis. The prostitutes in the second trial saw the advantage of the female condom as a back-up method for clients who refused to use the male condom. From the condom use data in the second trial, approximately 18% of brothel clients did not wish to wear the male condom but did not object to the woman using her own protection. Further research is urgently required to determine whether as high (or higher) levels of compliance and protection can be achieved in other brothel populations. Without the availability of the female condom, unprotected intercourse and disease transmission could have occurred. If this pattern is typical, then the female condom, as currently developed, could already play a signi® cant role in the prevention and control of HIV infection 18 .
INFORMATION
The female condom has recently become available. It is the only method of protection available for use by women themselves. However, there has been little information on the female condom for policy makers, programme managers and others involved in reproductive health. Women and men in the community need to know about the effectiveness, safety, correct use and disposal of the female condom, as well as how to avoid or overcome any potential problems. This information can be provided through a variety of different channels, including family planning and other health care services, community activities and the mass media. Men should not be neglected in the provision of information as their cooperation is important to sustain acceptability and use of the female condom.
The ® rst step in introducing the female condom, is to provide information to a wide range of groups, including decision-makers, programme managers, service providers, community leaders and women's and youth groups. These groups should be involved in the planning of the introduction of the female condom.
People need to be aware of what the product is and where it is available. Information materials should be made widely available within the community to both women and men. These should be presented in a manner which promotes discussion between partners and emphasizes the role of the female condom in prevention of both STD/HIV transmission as well as pregnancy.
The female condom can be distributed through a variety of channels, including family planning outlets, STD/HIV services, private health practitioners, pharmacies, social marketing programmes and school-based clinics. Systems must be established to ensure that distribution channels have a regular supply of the product.
In developed countries, the female condom is sold in pharmacies for between US$3.00 per condom. A special price of less than US$1.00 has been negotiated for the public sector in developing countries. As the demand increases, this price should decrease. However, because polyurethane is more expensive than latex the female condom is likely to remain more expensive than the latex male condom. Currently, it is recommended that each female condom be used only once. Studies are underway to assess the feasibility and safety of reuse in order to reduce costs to users.
EDUCATION
Training is needed for those people who will be providing the female condom so that it is presented in a positive, technically sound and culturally sensitive manner. Training should emphasize how to use the female condom, its ef® cacy and how providers can assist women to negotiate condom use with their partners. Studies have shown the importance of counselling in increasing acceptability and use of the female condom, as well as facilitating dialogue between women and men on sexual matters 19 .
In maternal and child health and family planning services, providers should be trained in STD/HIV risk assessment and be willing to discuss these issues with their clients. In STD clinics, providers should be trained to discuss the reproductive intentions of clients and to provide the female condom along with other barrier contraceptives. Furthermore, they should be able to refer clients to appropriate contraceptive service delivery facilities for other methods. Introduction of the female condom could be viewed as one step toward a more integrated approach to reproductive health.
Why do women need the female condom? A recent review from staff of WHO's reproductive health programme, and of UNAIDS 20 stated that, in the light of the AIDS pandemic, protection remains the most effective weapon against it and because of the following reasons.
Women's voices: women's health advocates have been encouraging the development of methods which women can control, which do not rely upon the assistance of a physician for use, and which are immediately reversible. Unfortunately, the contraceptives which are most effective in preventing unplanned pregnancy provide little, if any protection against STIs.
The spread of HIV: the proportion of HIV-infected adults who are women rose from 25% in 1990 to 45% by 1995 (9 millions). By the year 2000, more than 13 million women are projected to be infected with HIV and 4 million will have died from AIDS 21 .
Women in sexual relations: because of economic, social and gender inequalities, women are ill-placed to get their partners to use male condoms. Studies in some countries show that up to 30% of HIV infections are occurring in women whose only risk behaviour is sexual intercourse with a single male partner who in turn has had or continues to have unprotected sex with other partners 22 .
Adolescent girls: demand for younger sex partners who are less likely to be infected is growing, sparking the`sugar daddy' phenomenon. In Asia, urban-based brothel owners offer ® nancial incentives to rural families to sell their young daughters who are less likely to have contracted HIV or another STI 23 .
Other young women leave the countryside voluntarily to seek work in the urban sex-trade industry, in order to send money home to their families.
One study among African-American teenagers in the USA found that after an eight-week educational and skill-building intervention, female condom use persisted at a high level at the 12 month follow-up while male condom use gradually decreased 24 .
Greater physiological susceptibility: worldwide, the disease burden of STIs in women is ® ve times greater than in men 25 . Neisseria gonorrhoeae, Trichomonas vaginalis and Chlamydia trachomatis can increase the risk of HIV transmission from two to three fold, this risk being greater for women because the physical area exposed to sexual secretion is larger than that of men 26 .
Expanding choice: the more choices women have available, the more likely they are to use a method. Expanding choice also increases the percentage of sexual acts which are protected (against pregnancy and/or STIs/HIV). A study in Philadelphia reported that when women were given information about protective options for safer sex, and offered a free six-month supply of any method, 87% chose the female condom, 63% the male condom, 61% spermicidal foam, 57% spermicidal ® lm, 33% suppository, 11% diaphragm, 6% cervical cap. At the four-month follow-up, the male condom was being used by 65% while the female condom was being used by only 43%.
Among the group offered a combination of methods, those who used either female condoms or male condoms had a greatly improved per-sex-act coverage, compared to those who used only male condoms having an improved number of protected sex acts up from 27% to 52%. This suggests that when the female condom is available, people use either the male condom or the female condom more often 27 .
FUTURE DIRECTION
There are many obstacles ahead, however, including the cost of the device, the current level of donor support, unexplored research questions and lack of familiarity with this new product. But there are many positive signs as well. Research already indicates it offers some protection from STD/HIV. Many women and men like it and will use it when it is available. They will also use it when they have enough support from peers. And social marketing projects have found that men and women will continue buying the product, if it is available and affordable.
The female condom has symbolic value,' said Dr Ward Cates, Family Health International senior vice president for biomedical affairs 28 . It symbolizes the energy of expanding women's rights throughout the world and investing in a reproductive health agenda that helps women more broadly. It also represents an increased investment in barrier methods overall, for STD/HIV and pregnancy.' Increasing access to the female condom expands choices for all individuals. What is the next step in taking the female condom to the marketplace?
Among the more than 40 recommendations developed during the two days working conference,`The Female Condom: From Research to the Marketplace', held 1± 2 May, 1997, in Arlington, VA 29 six action steps can guide our work in the coming years.
1. Begin large scale introductions in two to three countries. 2. Promote the female condom for men as well as women. 3. Market the female condom simultaneously through interpersonal and all media strategies. 4. Expedite research on whether the female condom can be used more than once. 5. Provide incentives for alternative less expensive product designs. 6. Disseminate information broadly, including to the media.
In closing the conference, Montha Butler, resident advisor for AIDSCAP in the Dominican Republic, summarized the challenge ahead:`We need to move beyond our limits and unleash the power of our creativity to take action' she said.`Thus, while further research is pursued, the call is for the product to be made available now to all who wish to, and need to, use it. This is why empowerment is the crucial element here. People need to be empowered at the ® eld level, but also at the technical, donor, policy and decision-making levels. We need to empower ourselves to embrace this cause. We need to mobilize all in support of this opportunity to impact the advance of STDs and HIV.'
